中慧元通/怡道生物重组带状疱疹疫苗（CHO细胞）启动III期临床适应症为预防带状疱疹

动脉网10-11

江苏中慧元通生物科技有限公司与上海怡道生物科技有限公司联合研发的重组带状疱疹疫苗（CHO细胞）已启动Ⅲ期临床试验，登记号CTR20254023，首次公示日期为2025年10月11日。该疫苗为注射剂，用于40岁及以上成人预防带状疱疹，接种方式为上臂三角肌肌内注射，每次0.5mL，共接种2次，分别在第0月和第2月进行。试验主要目的是评价全程接种后36个月内预防带状疱疹的保护持久性，次要目的为评价36个...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2574465106?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-11 18:30","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2574465106","market":"hk","top_or_hot":-1,"title":"中慧元通/怡道生物重组带状疱疹疫苗（CHO细胞）启动III期临床适应症为预防带状疱疹","media":"动脉网","content":"<div>\n<p>江苏中慧元通生物科技有限公司与上海怡道生物科技有限公司联合研发的重组带状疱疹疫苗（CHO细胞）已启动Ⅲ期临床试验，登记号CTR20254023，首次公示日期为2025年10月11日。该疫苗为注射剂，用于40岁及以上成人预防带状疱疹，接种方式为上臂三角肌肌内注射，每次0.5mL，共接种2次，分别在第0月和第2月进行。试验主要目的是评价全程接种后36个月内预防带状疱疹的保护持久性，次要目的为评价36个...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101118443294c30be4&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中慧元通/怡道生物重组带状疱疹疫苗（CHO细胞）启动III期临床适应症为预防带状疱疹</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中慧元通/怡道生物重组带状疱疹疫苗（CHO细胞）启动III期临床适应症为预防带状疱疹\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-11 18:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101118443294c30be4&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>江苏中慧元通生物科技有限公司与上海怡道生物科技有限公司联合研发的重组带状疱疹疫苗（CHO细胞）已启动Ⅲ期临床试验，登记号CTR20254023，首次公示日期为2025年10月11日。该疫苗为注射剂，用于40岁及以上成人预防带状疱疹，接种方式为上臂三角肌肌内注射，每次0.5mL，共接种2次，分别在第0月和第2月进行。试验主要目的是评价全程接种后36个月内预防带状疱疹的保护持久性，次要目的为评价36个...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101118443294c30be4&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02627","symbol_name":"中慧生物-B","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101118443294c30be4&s=b","article_id":"2574465106","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101118443294c30be4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2574465106","pubTimestamp":1760178600,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"江苏中慧元通生物科技有限公司与上海怡道生物科技有限公司联合研发的重组带状疱疹疫苗（CHO细胞）已启动Ⅲ期临床试验，登记号CTR20254023，首次公示日期为2025年10月11日。该疫苗为注射剂，用于40岁及以上成人预防带状疱疹，接种方式为上臂三角肌肌内注射，每次0.5mL，共接种2次，分别在第0月和第2月进行。试验主要目的是评价全程接种后36个月内预防带状疱疹的保护持久性，次要目的为评价36个月免疫持久性。主要终点指标为全程接种后36个月内带状疱疹确诊病例的人年发病率，次要终点指标包括抗-gE抗体阳性率、GMC。目前试验状态为进行中，目标入组7500人。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"91190":"丹诺医药(苏州)股份有限公司（临时代码）","02627":"中慧生物-B","BK1161":"生物科技"},"translate_title":"Zhonghui Yuantong/Yidao Biological Recombinant Herpes Zoster Vaccine (CHO Cells) Starts Phase III Clinical Indication to Prevent Herpes Zoster","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91190":1.5,"02627":0.9},"content_text":"江苏中慧元通生物科技有限公司与上海怡道生物科技有限公司联合研发的重组带状疱疹疫苗（CHO细胞）已启动Ⅲ期临床试验，登记号CTR20254023，首次公示日期为2025年10月11日。该疫苗为注射剂，用于40岁及以上成人预防带状疱疹，接种方式为上臂三角肌肌内注射，每次0.5mL，共接种2次，分别在第0月和第2月进行。试验主要目的是评价全程接种后36个月内预防带状疱疹的保护持久性，次要目的为评价36个月免疫持久性。主要终点指标为全程接种后36个月内带状疱疹确诊病例的人年发病率，次要终点指标包括抗-gE抗体阳性率、GMC。目前试验状态为进行中，目标入组7500人。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2574465106","isCrawlerRequest":true}